ST-193

Research use only, not for human use.

ST-193 (ST193) is a potent, selective, broad-spectrum arenavirus entry inhibitor with IC50 of 1.6 nM against LASV pseudotypes, targets arenavirus envelope glycoprotein.

ST-193 (ST193) is a potent, selective, broad-spectrum arenavirus entry inhibitor with IC50 of 1.6 nM against LASV pseudotypes, targets arenavirus envelope glycoprotein; Also inhibits pseudotypes generated with other arenavirus envelopes with IC50 of 0.2-12 nM, but exhibited no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus LCMV or the unrelated G protein from vesicular stomatitis virus (IC50>10 uM); exhibits antiviral activity against Lassa virus (LASV) in a guinea pig model (i.p.).

ST-193 inhibits LASV pseudotypes with an IC50 of 1.6 nM. ST-193 inhibits pseudotypes generated with other arenavirus envelopes as well, including the remaining four commonly associated with hemorrhagic fever (IC50s for Junín, Machupo, Guanarito, and Sabiá were in the 0.2 to 12 nM range) but exhibits no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus lymphocytic choriomeningitis virus or the unrelated G protein from vesicular stomatitis virus, at concentrations of up to 10 μM.

ST-193 is found to be tolerated well when administered daily as an intraperitoneal injection of either 25 or 100 mg/kg/day for 14 days. ST-193-treated animals exhibit fewer signs of disease and enhance survival when compared to the ribavirin or vehicle groups. Body temperatures in all groups are elevated by day 9, but returned to normal by day 19 postinfection in the majority of ST-193-treated animals. ST-193 treatment mediates a 2- to 3-log reduction in viremia relative to vehicle-treated controls. The overall survival rate for the ST-193-treated guinea pigs is 62.5% (10/16) compared with 0% in the ribavirin (0/8) and vehicle (0/7) groups.

ST193 | ST 193

Microbiology/Virology

Arenavirus

Arenavirus

——

——

489416-12-8

371.4748

C24H25N3O

>98% (HPLC)

DMSO: ≥ 150 mg/mL

CC(C)C1=CC=C(C=C1)CNC2=CC3=C(C=C2)N(C=N3)C4=CC=C(C=C4)OC

1H-Benzimidazol-5-amine, 1-(4-methoxyphenyl)-N-[[4-(1-methylethyl)phenyl]methyl]-

(-20℃)

With Ice Pack

≥ 2 years